Welcome to Browse Page of Biomarker

This page shows the result of browsing biomarker from different fieldss.For more information see HELP page.

The total number entries retrieved from this search are 594
Please click on Biomarker_ID to view detailed information.
Note: Potential Biomarker with * indicates these signatures are candidate biomarkers extracted from experiments on mice, rat or cell lines and they are not validated on human patients'cohort.
Biomarker IDBiomarkerBiomoleculeSubjectRegulationBiomarker's typeExperimentLevel of significanceSourcePMID
2101MSMO1RNAsHumanDownregulated in JFH-1-infected Huh7 cells (with log fold change more than 1) DiagnosticNormal vs HCC FDR <0.01Cells26811688
2102CPERNAsHumanCPE expression level was also significantly correlated with the tumor recurrence for both stage i.e. Stage-I and Stage-II PrognosticRecurrence between stage-I v/s stage-II p < 0.01Tissue26803519
2103AFP-L3ProteinHumanUpregulated in AFP-negative HCC patients DiagnosticNormal vs HCC p < 0.01Tissue26770061
2104GP73ProteinHumanUpregulated in AFP-negative HCC patients DiagnosticNormal vs HCC p < 0.01Tissue26770061
2105AFP-L3, GP73 (combined)ProteinHumanUpregulated in AFP-negative HCC patients DiagnosticNormal vs HCC p < 0.01Tissue26770061
2106TOPO2ProteinHumanDownregulated in nucleolus of HCC DiagnosticNormal vs HCC NATissue26722553
2107Combination of S100A9 and GRNOthersHumanDownregulated in HCC patients Diagnostic and PrognosticNormal vs HCC p < 0.001Urine26675302
2108ABCC3ProteinRat and Humanoverexpressed in hepatocellular carcinoma Potential Diagnostic *Normal vs HCC p < 0.01Tissue26337276
2109DHCR24 Auto-antibodyProteinHumanUpregulated in CHC (Chronic Hepatitis C) v/s healthy PrognosticNormal vs Chronic heaptitis (CHV) p < 0.0001Serum26288822
2110DHCR24 Auto-antibodyProteinHumanDHCR24 was up-regulated in HCV-positive, but not HBV-positive tissues or HBV-negative, HCV-negative HCC PrognosticHCC vs Chronic heaptitis (CHV)/healthy/Liver cirrhosis p < 0.0001Serum26288822
2111qEASLMethod (Others)HumanNA Predictive TACE responder v/s TACE non-responder p < 0.05Tissue26131913
2112vRECISTMethod (Others)HumanNA Predictive TACE responder v/s TACE non-responder p < 0.05Tissue26131913
2113Alpha-ketoglutaricMetaboliteHumanThe concentrations of α-KG in diabetic II and liver cancer urine samples were significantly lower than those from healthy people. DiagnosticNormal vs cancer p < 0.05Urine25871588
2114pyruvic acidMetaboliteHumanThe concentrations of PA in diabetic II and liver cancer urine samples were significantly lower than those from healthy people. DiagnosticNormal vs cancer p < 0.05Urine25871588
2115Galectin-1ProteinHuman High pretreatment galectin-1 levels remained an independent predictor of shorter progression-free survival and overall survival PredictiveHCC patients treated with sorafenib vs HCC untreated patients p < 0.01Serum25850433
2116miR-128-2miRNAHumanUpregulated in HCC tissues PrognosticHCC v/s Normal, predict survival of patients p < 0.01Serum25642945
2117RNase AProteinHumanDownregulated in gastric cancer, liver cancer, pancreatic cancer, esophageal cancer, ovary cancer, cervical cancer, bladder cancer, kidney cancer and lung cancer DiagnosticCancer v/s Normal p < 0.01Serum24805924
2118HNF4A, RelAmiRNAHumanupregulated in hepatoma cells PrognosticL-HNF4α group v/s hig-HNF4α group; associated with survival of patients p < 0.05Tissue24752868
2119KIAA1114ProteinHuman and Mice cell linesKIAA1114 is overexpressed in human liver cancer cell lines Potential Diagnostic *Normal cell line vs HCC cell line p < 0.05Tissue24713374
2120D-glucurono-6,3-lactoneMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2121glycerol-3-phosphateMetaboliteMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2122pyruvic acidMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2123lithocholic acidMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
21242-pyrocatechuic acidMetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2125prostaglandin E1MetabolitesMiceUpregulated in AFLD Potential Predictive *Serum biochemical analysis, antioxidant enzyme activity analysis, and histopathological evaluation revealed that GEO and citral exhibited hepatoprotective activity against AFLD. Metabolites in serum samples were profiled Serum24171385
2126AFP (at a cut-off of 20 ng/mL)ProteinHumanUpregulated level in HCC DiagnosticHCC with cirrhosis v/s HCV-associated cirrhosis p < 0.05Serum24095974
2127DNA hypomethylated regions of GPM6BEpigenetic (Others)Humanhypomethylated and Upregulated level in HCC DiagnosticCancer v/s Normal p < 0.01Tissue23950870
2128DNA hypomethylated regions of MAGEA12Epigenetic (Others)Humanhypomethylated and Upregulated level in HCC DiagnosticCancer v/s Normal p < 0.01Tissue23950870
2129DNA hypomethylated regions of FCRL1Epigenetic (Others)Humanhypomethylated and Upregulated level in HCC DiagnosticInvasive HCC v/s non-invasive HCC p < 0.01Tissue23950870
2130VTNProteinHumanDownregulated in HCV-infected HCC patients DiagnosticNormal vs HCV-infected HCC patients, Normals vs non HCV-infected HCC p < 0.05Plasma23944848
2131SAPProteinHumanDownregulated in HCV-infected HCC patients DiagnosticNormal vs HCV-infected HCC patients, Normals vs non HCV-infected HCC p < 0.01Plasma23944848
2132CYP3A4ProteinHumanUpregulated in in hepatitis B virus-associated liver cirrhosis and stage I hepatocellular carcinoma, PrognosticHCC vs adjacent non-tumor and stageII v/s stage-III; predict early stage p < 0.05Tissue and Cells 23891548
2133miR-1miRNAHumanIncreasead concentration showed longer OS in HCC PrognosticHCC v/s Liver Cirrhosis; predict survival of patients p < 0.01Serum23810247
2134ENO1ProteinHumanUpregulated in patients with precirrhotic stage of liver fibrosis than that in patients with cirrhosis/liver cancer/healthy individuals. PrognosticLiver fibrosis v/s cirrhosis/liver cancer/normal; predict early stage of disease p < 0.01Serum23458688
2135XPO4ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2136TGFβ1ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2137elF5A2ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2138ANGPTL4ProteinHumanUpregulated in paracancerous than in cancerous liver tissue PrognosticNormal vs HCC; predict survival of patients p < 0.0001Tissue23251252
2139C3ProteinMale Wistar ratsUpregulated at very early stage in HCC Potential Diagnostic *Normal vs HCC p < 0.05Tissue23245919
2140miR-18b*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.21) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2141miR-296-5pmiRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.16) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2142miR-557miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.29) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2143miR-581miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.10) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2144miR-625*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.23) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2145miR-1228miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.30) DiagnosticNormal v/s HCC/HCV/HBV p < 0.01Tissue23205106
2146miR-1249miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.20) DiagnosticNormal v/s HCC/HCV/HBV p < 0.001Tissue23205106
2147miR-2116*miRNAHumanDownregulated in the HCC v/s non-tumor (with fold change 0.048) DiagnosticNormal v/s HCC/HCV/HBV p < 0.05Tissue23205106
2148miR-129*miRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2149miR-146b-3pmiRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106
2150miR-448miRNAHumanDownregulated in the HCC v/s non-tumor DiagnosticNormal vs HCC, liver cancer p < 0.05Tissue23205106

         Raghava's group    CancerCSP    CancerSPP    CancerPDF    CancerTSP    CancerLSP    HCCPred   

Scroll to Top